Acadia Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Acadia Pharmaceuticals (ACAD).

Price Target Range — 10 Quarters

Analyst Consensus — 21 Analysts

2S.Buy

14Buy

4Hold

1Sell

Consensus RatingBuy# Analysts21Avg. Consensus PT$30Upside to Avg. PT+48.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 13, 2026	UBS	Ashwani Verma	Downgrade	Buy→Neutral	$49→$23
Oct 8, 2026	RBC Capital	Brian Abrahams	PT Cut	Outperform	$37→$36
Sep 25, 2026	Deutsche Bank	David Hoang	PT Cut	Buy	$38→$31
Sep 25, 2026	HC Wainwright & Co.	Ananda Ghosh	PT Cut	Buy	$37→$33
Sep 25, 2026	Citizens	Jason N. Butler	PT Cut	Market Outperform	$36→$33
Sep 25, 2026	BMO Capital	Evan David Seigerman	PT Cut	Outperform	$36→$34
Sep 25, 2026	Needham	Ami Fadia	PT Cut	Buy	$41→$35
Sep 24, 2026	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$40→$33
Sep 24, 2026	Needham	Ami Fadia	Maintained	Buy	$41
Aug 25, 2026	Deutsche Bank	David Hoang	PT Raise	Buy	$37→$38
Aug 25, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Equal-Weight	$27→$28
Aug 25, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$39→$40
Aug 17, 2026	UBS	Ashwani Verma	PT Raise	Buy	$45→$49
Aug 12, 2026	Needham	Ami Fadia	PT Raise	Buy	$38→$41
Aug 10, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$35→$39
Aug 5, 2026	Oppenheimer	Matthew Hershenhorn	PT Raise	Perform	$23→$25
Aug 5, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$36→$37
Aug 5, 2026	Citizens	Jason N. Butler	PT Raise	Market Outperform	$35→$36
Jul 21, 2026	Stifel	Paul Matteis	PT Raise	Hold	$24→$25
Jul 21, 2026	BMO Capital	Evan David Seigerman	PT Raise	Outperform	$34→$36

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Downgrades Acadia Pharmaceuticals to Neutral, Lowers Price Target to $23

UBS analyst Ashwani Verma downgrades Acadia Pharmaceuticals (NASDAQ:ACAD) from Buy to Neutral and lowers the price target from $49 to $23.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Acadia Pharmaceuticals, Lowers Price Target to $36

RBC Capital analyst Brian Abrahams maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price target from $37 to $36.

Benzinga Newsdesk

PRO
Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $31

Deutsche Bank analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $38 to $31.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33

HC Wainwright & Co. analyst Ananda Ghosh maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $37 to $33.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $33

Citizens analyst Jason N. Butler maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Market Outperform and lowers the price target from $36 to $33.

Benzinga Newsdesk

PRO
BMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $34

BMO Capital analyst Evan David Seigerman maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price target from $36 to $34.

Benzinga Newsdesk

Acadia Pharmaceuticals Inc

Acadia Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
UBS Downgrades Acadia Pharmaceuticals to Neutral, Lowers Price Target to $23

PRO
RBC Capital Maintains Outperform on Acadia Pharmaceuticals, Lowers Price Target to $36

PRO
Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $31

PRO
HC Wainwright & Co. Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33

PRO
Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $33

PRO
BMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $34

People Also Watch

People Also Watch

Acadia Pharmaceuticals Inc

Acadia Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROUBS Downgrades Acadia Pharmaceuticals to Neutral, Lowers Price Target to $23

PRORBC Capital Maintains Outperform on Acadia Pharmaceuticals, Lowers Price Target to $36

PRODeutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $31

PROHC Wainwright & Co. Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33

PROCitizens Maintains Market Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $33

PROBMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $34

People Also Watch

People Also Watch

PRO
UBS Downgrades Acadia Pharmaceuticals to Neutral, Lowers Price Target to $23

PRO
RBC Capital Maintains Outperform on Acadia Pharmaceuticals, Lowers Price Target to $36

PRO
Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $31

PRO
HC Wainwright & Co. Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33

PRO
Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $33

PRO
BMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $34